B-cell-depleting therapies (BCDTs), including anti-CD20 monoclonal antibodies, such as ocrelizumab and ofatumumab [16], and Bruton’s tyrosine kinase (BTK) inhibitors, such as tolebrutinib and fenebrutinib [37], decrease MS activity and brain lesions. The gene discussed is BTK; the disease is myeloid sarcoma.